101. Secretory leukocyte protease inhibitor as a novel predictive biomarker in patients with diabetic kidney disease
- Author
-
Weiwei Sun, Hanwen Yang, Jiale Zhang, Shuwu Wei, Qiaoru Wu, Jie Yang, Can Cao, Zhaoli Cui, Huijuan Zheng, and Yaoxian Wang
- Subjects
diabetic kidney disease ,secretory leucocyte protease inhibitor ,prognosis ,renal clinical endpoint events ,biomarkers ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundSecretory leukocyte protease inhibitor (SLPI) is a multifunctional protein involved in the chronic inflammatory process, implicated in the pathogenesis of diabetic kidney disease (DKD). However, its potential as a diagnostic and prognostic biomarker of DKD has yet to be evaluated. This study explored the clinical utility of SLPI in the diagnosis and prognosis of renal endpoint events in patients with DKD.MethodsA multi-center cross-sectional study comprised of 266 patients with DKD and a predictive cohort study comprised of 120 patients with stage IV DKD conducted between December 2016 and January 2022. The clinical parameters were collected for statistical analysis, a multivariate Cox proportional hazards model was used to evaluate the independent risk factors for renal endpoints.ResultsSerum SLPI levels gradually increased with DKD progression (p
- Published
- 2024
- Full Text
- View/download PDF